Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial-Reference-Cited by-同舟云学术

Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial

Published:2023-12 Issue:12 Volume:24 Page:1387-1398
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Taniguchi Cullen M,Frakes Jessica M,Aguilera Todd A,Palta Manisha,Czito Brian,Bhutani Manoop S,Colbert Lauren E,Abi Jaoude Joseph,Bernard Vincent,Pant Shubham,Tzeng Ching-Wei D,Kim Dae Won,Malafa Mokenge,Costello James,Mathew Geena,Rebueno Neal,Koay Eugene J,Das Prajnan,Ludmir Ethan B,Katz Matthew H G,Wolff Robert A,Beddar Sam,Sawakuchi Gabriel O,Moningi Shalini,Slack Tidwell Rebecca S,Yuan Ying,Thall Peter F,Beardsley Robert A,Holmlund Jon,Herman Joseph M,Hoffe Sarah E

Funder

National Cancer Institute

Aldeyra Therapeutics

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease;Katz;J Am Coll Surg,2008

2. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial;Hammel;JAMA,2016

3. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study